HVB MINI FUTURE BULL - ASTRAZENECA | Market Closed - Boerse Frankfurt Warrants 11:09:00 03/05/2024 pm IST | ||
| 6.02 EUR | -1.79% |
|
| Current month | +0.50% | ||
| 1 month | +39.68% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/24/03 | 6.02 | -1.79% | 0 |
| 02/24/02 | 6.13 | +2.34% | 0 |
| 30/24/30 | 5.99 | -0.50% | 0 |
| 29/24/29 | 6.02 | +0.17% | 0 |
| 26/24/26 | 6.01 | +0.84% | 0 |
Real-time Boerse Frankfurt Warrants
Last update May 03, 2024 at 11:09 pm IST
More quotesStatic data
| Product type | Knock-Out con Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HR5TY3 |
| ISIN | DE000HR5TY32 |
| Date issued | 25/02/2021 |
| Strike | 6,886 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.07 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.63 € |
|---|---|
| Lowest since issue | 0.68 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
151.2
USD
Average target price
164.5
USD
Spread / Average Target
+8.76%
- Stock Market
- Certificates
- Certificat
